首页> 外文期刊>Diabetes >Clinical and Molecular Characterization of a Novel PLIN1 Frameshift Mutation Identified in Patients With Familial Partial Lipodystrophy
【24h】

Clinical and Molecular Characterization of a Novel PLIN1 Frameshift Mutation Identified in Patients With Familial Partial Lipodystrophy

机译:家族性部分脂肪营养不良患者中鉴定的新型PLIN1移码突变的临床和分子表征

获取原文
获取原文并翻译 | 示例
       

摘要

Perilipin 1 is a lipid droplet coat protein predominantly expressed in adipocytes, where it inhibits basal and facilitates stimulated lipolysis. Loss-of-function mutations in the PLIN1 gene were recently reported in patients with a novel subtype of familial partial lipodystrophy, designated as FPLD4. We now report the identification and characterization of a novel heterozygous frameshift mutation affecting the carboxy-terminus (439fs) of perilipin 1 in two unrelated families. The mutation cosegregated with a similar phenotype including partial lipodystrophy, severe insulin resistance and type 2 diabetes, extreme hypertriglyceridemia, and nonalcoholic fatty liver disease in both families. Poor metabolic control despite maximal medical therapy prompted two patients to undergo bariatric surgery, with remarkably beneficial consequences. Functional studies indicated that expression levels of the mutant protein were lower than wild-type protein, and in stably transfected preadipocytes the mutant protein was associated with smaller lipid droplets. Interestingly, unlike the previously reported 398 and 404 frameshift mutants, this variant binds and stabilizes ABHD5 expression but still fails to inhibit basal lipolysis as effectively as wild-type perilipin 1. Collectively, these findings highlight the physiological need for exquisite regulation of neutral lipid storage within adipocyte lipid droplets, as well as the possible metabolic benefits of bariatric surgery in this serious disease.
机译:Perilipin 1是主要在脂肪细胞中表达的脂质小滴外套蛋白,在其中它抑制基础并促进刺激性脂解。最近有一种新型家族性部分脂肪营养不良亚型(称为FPLD4)的患者报道了PLIN1基因的功能丧失突变。我们现在报告鉴定和表征影响两个无关家族perilipin 1的羧基末端(439fs)的新型杂合移码突变。该突变与两个家族的相似表型共分离,包括部分脂肪营养不良,严重的胰岛素抵抗和2型糖尿病,极端高甘油三酯血症和非酒精性脂肪肝。尽管进行了最大程度的药物治疗,但新陈代谢控制不佳促使两名患者进行了减肥手术,产生了明显有益的后果。功能研究表明,突变蛋白的表达水平低于野生型蛋白,在稳定转染的前脂肪细胞中,突变蛋白与较小的脂质滴相关。有趣的是,与先前报道的398和404移码突变体不同,该变体结合并稳定了ABHD5表达,但仍不能像野生型perilipin 1一样有效地抑制基础脂解。总的来说,这些发现凸显了对中性脂质存储进行精确调节的生理需要在这种严重疾病中,脂肪细胞内的脂质滴以及减肥手术可能带来的新陈代谢益处。

著录项

  • 来源
    《Diabetes》 |2015年第1期|299-310|共12页
  • 作者单位

    University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, U.K.;

    Diabetes Centre and Department of Endocrinology, St Vincent's Hospital, Sydney, Australia;

    Wellcome Trust Sanger Institute, University of Cambridge, Hinxton, U.K.;

    Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Sydney, Australia,Discipline of Paediatrics and Child Health, The Children's Hospital at Westmead Clinical School, University of Sydney, Sydney, Australia;

    Council of Scientific and Industrial Research-Institute of Genomics & Integrative Biology, New Delhi, India;

    University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, U.K.;

    University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, U.K.;

    University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, U.K.;

    University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, U.K.;

    University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, U.K.;

    University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, U.K.;

    Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Sydney, Australia;

    Diabetes Centre and Department of Endocrinology, St Vincent's Hospital, Sydney, Australia,Diabetes and Obesity Research Program, Garvan Institute of Medical Research, Sydney, Australia;

    Wellcome Trust Sanger Institute, University of Cambridge, Hinxton, U.K.;

    Diabetes Centre and Department of Endocrinology, St Vincent's Hospital, Sydney, Australia,Diabetes and Obesity Research Program, Garvan Institute of Medical Research, Sydney, Australia;

    University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, U.K.;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 03:46:14

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号